Saturday - June 13, 2026
FDA Approves Label Expansion, Cementing TREMFYA as the Only IL 23 Inhibitor Proven to Help Stop Further Joint Damage
May 29, 2026
RARITAN, New Jersey, May 29 -- Johnson and Johnson Innovative Medicine issued the following news release on May 28, 2026:

* * *

FDA approves label expansion, cementing TREMFYA(R) as the only IL 23 inhibitor proven to help stop further joint damage

TREMFYA(R) showed significant inhibition of structural joint damage in adults with active psoriatic arthritis

-

HORSHAM, PA - Johnson & Johnson (NYSE: JNJ) announced today that the U. . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products